Steffensen KD - Search Results

1

The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer.

Steffensen KD, Waldstrøm M, Jeppesen U, Jakobsen E, Brandslund I, Jakobsen A. Steffensen KD, et al. Int J Gynecol Cancer. 2007 Jul-Aug;17(4):798-807. doi: 10.1111/j.1525-1438.2006.00855.x. Epub 2007 Feb 16. Int J Gynecol Cancer. 2007. PMID: 17309668

2

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.

Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I, Jakobsen A. Steffensen KD, et al. Int J Gynecol Cancer. 2008 Jul-Aug;18(4):702-10. doi: 10.1111/j.1525-1438.2007.01068.x. Epub 2007 Oct 24. Int J Gynecol Cancer. 2008. PMID: 17961161 Clinical Trial.

3

Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors.

Steffensen KD, Waldstrøm M, Olsen DA, Corydon T, Lorentzen KA, Knudsen HJ, Jeppesen U, Brandslund I, Jakobsen A. Steffensen KD, et al. Clin Cancer Res. 2008 Jun 1;14(11):3278-82. doi: 10.1158/1078-0432.CCR-07-4171. Clin Cancer Res. 2008. PMID: 18519753 Free article.

4

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.

Steffensen KD, Waldstrøm M, Andersen RF, Olsen DA, Jeppesen U, Knudsen HJ, Brandslund I, Jakobsen A. Steffensen KD, et al. Int J Oncol. 2008 Jul;33(1):195-204. Int J Oncol. 2008. PMID: 18575766

5

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance.

Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I, Mor G. Alvero AB, et al. Among authors: steffensen kd. Cell Cycle. 2009 Jan 1;8(1):158-66. doi: 10.4161/cc.8.1.7533. Cell Cycle. 2009. PMID: 19158483 Free PMC article.

6

Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer.

Smerdel MP, Waldstrøm M, Brandslund I, Steffensen KD, Andersen RF, Jakobsen A. Smerdel MP, et al. Among authors: steffensen kd. Int J Gynecol Cancer. 2009 May;19(4):578-84. doi: 10.1111/IGC.0b013e3181a13168. Int J Gynecol Cancer. 2009. PMID: 19509553

7

The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.

Steffensen KD, Waldstrøm M, Jakobsen A. Steffensen KD, et al. Int J Gynecol Cancer. 2009 Jul;19(5):820-5. doi: 10.1111/IGC.0b013e3181a12e09. Int J Gynecol Cancer. 2009. PMID: 19574766

8

The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer.

Steffensen KD, Waldstrøm M, Brandslund I, Jakobsen A. Steffensen KD, et al. Gynecol Oncol. 2010 Apr;117(1):109-16. doi: 10.1016/j.ygyno.2009.11.011. Epub 2010 Jan 6. Gynecol Oncol. 2010. PMID: 20056267

9

Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.

Steffensen KD, Waldstrøm M, Christensen RK, Bartels A, Brünner N, Jakobsen A. Steffensen KD, et al. BMC Cancer. 2010 May 7;10:185. doi: 10.1186/1471-2407-10-185. BMC Cancer. 2010. PMID: 20459644 Free PMC article.

10

The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.

Smerdel MP, Steffensen KD, Waldstrøm M, Brandslund I, Jakobsen A. Smerdel MP, et al. Among authors: steffensen kd. Gynecol Oncol. 2010 Aug 1;118(2):167-71. doi: 10.1016/j.ygyno.2010.03.018. Epub 2010 May 14. Gynecol Oncol. 2010. PMID: 20471067

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

100 results

Search Page

Filters